Newsletter SignupSearch

Publication

Cross-Platform Evaluation of Commercially Targeted and Untargeted Metabolomics Approaches to Optimize the Investigation of Psychiatric Disease

Citation:
Metabolites. 2021 Sep 8;11(9):609. doi: 10.3390/metabo11090609.
Authored By:
Lauren E Chaby, Heather C Lasseter, Kévin Contrepois, Reza M Salek, Christoph W Turck, Andrew Thompson, Timothy Vaughan, Magali Haas, Andreas Jeromin
Abstract:
Metabolomics methods often encounter trade-offs between quantification accuracy and coverage, with truly comprehensive coverage only attainable through a multitude of complementary assays. Due to the lack of standardization and the variety of metabolomics assays, it is difficult to integrate datasets across studies or assays. To inform metabolomics platform selection, with a focus on posttraumatic stress disorder (PTSD), we review platform use and sample sizes in psychiatric metabolomics studies and then evaluate five prominent metabolomics platforms for coverage and performance, including intra-/inter-assay precision, accuracy, and linearity. We found performance was variable between metabolite classes, but comparable across targeted and untargeted approaches. Within all platforms, precision and accuracy were highly variable across classes, ranging from 0.9-63.2% (coefficient of variation) and 0.6-99.1% for accuracy to reference plasma. Several classes had high inter-assay variance, potentially impeding dissociation of a biological signal, including glycerophospholipids, organooxygen compounds, and fatty acids. Coverage was platform-specific and ranged from 16-70% of PTSD-associated metabolites. Non-overlapping coverage is challenging; however, benefits of applying multiple metabolomics technologies must be weighed against cost, biospecimen availability, platform-specific normative levels, and challenges in merging datasets. Our findings and open-access cross-platform dataset can inform platform selection and dataset integration based on platform-specific coverage breadth/overlap and metabolite-specific performance.
Published in:
Metabolites

More Publications

September 9, 2022

Sensors

Deep Learning for Daily Monitoring of Parkinson’s Disease Outside the Clinic Using Wearable Sensors

June 1, 2022

JAMA Network Open

Association of Posttraumatic Stress Disorder With Accelerated Cognitive Decline in Middle-aged Women

March 23, 2022

Journal of Neurotrauma

A Framework to Advance Biomarker Development in the Diagnosis, Outcome Prediction, and Treatment of Traumatic Brain Injury

February 26, 2022

Translational Psychiatry

Plasma biomarkers associated with deployment trauma and its consequences in post-9/11 era veterans: initial findings from the TRACTS longitudinal cohort

January 31, 2022

Biological Psychiatry

Noncoding RNAs: Stress, Glucocorticoids, and Posttraumatic Stress Disorder

December 1, 2021

Neurotrauma Reports

Neurotrauma Reports Special Collection: Null Hypothesis Initiative

Cohen Veterans Bioscience - Advancing Brain Health

Get the latest updates in TBI and PTSD research

Sign up for our newsletter to learn how we’re advancing solutions for brain trauma.

This field is for validation purposes and should be left unchanged.